The cells at the center of the story are podocytes, highly specialized epithelial cells that wrap around the tiny capillary loops of the glomerulus, the kidney’s filtration unit. Podocytes extend intricate foot processes that interlock to form slits through which blood is filtered, and their integrity is essential for keeping protein from leaking into the urine. When podocytes are injured or lost, the filtration barrier breaks down, proteinuria develops, and progressive scarring follows. Podocyte injury is widely regarded as a decisive event in diabetic kidney disease, which is why understanding exactly how high blood sugar damages these cells has become one of the most pressing questions in nephrology.

The new research focuses on an unexpected player: FTO, the fat-mass and obesity-associated protein. FTO first rose to fame through genome-wide association studies linking variants in its gene to human obesity, but it was later shown to be an enzyme that removes a specific chemical modification from RNA molecules. That modification, N6-methyladenosine, or m6A, is the most abundant internal mark on messenger RNA in higher organisms. By adding or erasing m6A, cells can fine-tune how long a given mRNA survives, how efficiently it is translated into protein, and how it is processed. In earlier work, the team had manipulated FTO in podocytes and performed parallel methylated RNA immunoprecipitation sequencing and RNA sequencing, a combination that reveals both which transcripts carry m6A marks and how overall gene expression changes. That screen pointed them toward early growth response 1, or EGR1, a transcription factor whose precise role in diabetic kidney disease had remained unclear.

The findings that followed connect the dots in a strikingly mechanistic way. The researchers demonstrated that FTO is critical to podocyte injury because it enhances the stability of EGR1 mRNA in a manner dependent on m6A and on YTHDF2, a reader protein that binds methylated RNA and directs its fate. In other words, by removing methyl marks from the EGR1 transcript, FTO protects that message from YTHDF2-mediated degradation, allowing more EGR1 protein to be produced. The team also found that EGR1 is elevated in podocytes taken from people with diabetic kidney disease, and that its levels correlate with estimated glomerular filtration rate and with 24-hour urinary protein, two clinical measures of how well the kidney is functioning and how badly the filter is leaking.

Experiments in cultured human podocytes reinforced the picture. When the cells were exposed to high glucose, mimicking the diabetic environment, EGR1 expression climbed. Silencing EGR1 eased both the injury and the inflammation that high glucose provokes in podocytes, while forcing the cells to overproduce EGR1 made the damage worse. This dose-and-direction relationship, in which turning the gene down protects and turning it up harms, is exactly what one would expect from a genuine driver of the disease process rather than a passive bystander.

The mechanistic core of the study lies in what EGR1 does once it is produced. Using chromatin immunoprecipitation, the researchers showed that EGR1 binds directly to the promoter of STING1, the gene encoding stimulator of interferon genes 1, a protein better known as a central hub of innate immune signaling. By occupying its promoter, EGR1 boosts STING1 transcription, which in turn activates the STING1/TBK1/NF-κB signaling cascade. This cascade is a classic inflammatory pathway: STING1 activates TBK1, a kinase that then activates NF-κB, a transcription factor that switches on a battery of inflammatory genes. The result is a self-reinforcing inflammatory attack on the podocyte from within, driven ultimately by an RNA modification laid down by FTO.

To test whether the pathway matters in a living organism, the team turned to mouse models of diabetes induced by streptozotocin and a high-fat diet, which together reproduce key features of the human disease. Using adeno-associated virus vectors to deliver genetic constructs specifically to podocytes, they deleted or upregulated EGR1 in these cells. The outcome was unambiguous. Podocyte-specific deletion of EGR1 significantly reduced podocyte and glomerular damage in the diabetic mice, preserving the structure of the filtration barrier. Conversely, when EGR1 was deliberately elevated in podocytes, the mice suffered worse podocyte injury and heavier proteinuria. The same gene that protected cells when removed caused harm when amplified, confirming EGR1 as a pivotal node in the disease cascade in vivo.

The study is notable for the way it stitches together three layers of biology that are usually studied separately: epitranscriptomics, the chemistry of RNA modifications; transcriptional regulation, the control of gene expression by DNA-binding factors; and innate immunity, the inflammatory machinery that cells deploy against perceived threats. In the podocytes of a diabetic kidney, these layers converge into a single pathway. High glucose and FTO activity conspire to stabilize EGR1 mRNA, EGR1 protein then switches on STING1, and the STING1/TBK1/NF-κB axis ignites inflammation that erodes the kidney’s filter. Each link in that chain is a potential point of intervention, and the authors suggest that EGR1 itself could be a prospective new treatment strategy for diabetic kidney disease.

The clinical stakes are considerable. Current therapy for diabetic kidney disease rests on controlling blood glucose and blood pressure and on blocking the renin-angiotensin system with drugs such as angiotensin-converting enzyme inhibitors, alongside newer agents including SGLT2 inhibitors. Yet a large fraction of patients still progress toward dialysis or transplant, so molecular targets that address the injury process itself, rather than its systemic drivers, are eagerly sought. Because EGR1 sits downstream of FTO and upstream of the inflammatory cascade, drugging it or its partners might blunt podocyte inflammation even when metabolic control is imperfect. Any such approach would need to reckon with the fact that EGR1 is an immediate-early transcription factor with many roles in other tissues, so specificity will be a central challenge for future drug development.

There are also caveats that temper the excitement. The human evidence consists of correlations between EGR1 levels in podocytes and clinical markers, which, while consistent with the mechanistic data, cannot by themselves prove causation in patients. The mouse model, though well established, does not capture every feature of human diabetic nephropathy, and the viral vectors used to manipulate EGR1 in podocytes are research tools rather than therapeutic vehicles. The published version of the study is open access, allowing clinicians and researchers worldwide to scrutinize the data, and the work was approved by the relevant ethics committees at Shandong Provincial Hospital with informed consent from all participants. Even so, the study offers something the field has lacked: a complete, testable narrative linking an RNA demethylase, a methylated mRNA, an immune signaling hub, and the slow-motion catastrophe of the diabetic glomerulus. If that narrative holds up in further studies, the humble chemical tag on a strand of RNA may turn out to be one of diabetes’ most consequential accomplices, and shutting down its effects could help millions of people keep their kidneys working longer.

Subject of Research: FTO-mediated m6A modification of EGR1 mRNA and its role in podocyte injury and inflammation in diabetic kidney disease

Article Title: FTO-mediated m6A modification of EGR1 mRNA promotes podocyte injury and inflammation via STING1 in diabetic kidney disease

Article References: Hu, J., Liu, Y., Lang, Y., Liu, B., Fan, X., Yang, M., Shen, N., Zhang, D., Zhang, X., Chai, S., Zeng, Z., Shang, J., Wang, R., & Lv, Z. (2026). FTO-mediated m6A modification of EGR1 mRNA promotes podocyte injury and inflammation via STING1 in diabetic kidney disease. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06474-w

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06474-w

Keywords: diabetic kidney disease, podocytes, FTO, EGR1, STING1, m6A modification, RNA demethylase, YTHDF2, NF-kappaB, inflammation, proteinuria, nephrology

The gene in question is STING1, also known as TMEM173, which encodes the stimulator of interferon genes, or STING, protein. STING sits at the heart of the cGAS-STING pathway, a cytosolic DNA-sensing system that acts as a cellular alarm. When double-stranded DNA appears in the cytoplasm, whether from HIV reverse transcription intermediates, from damaged mitochondria, or from the mislocalized host DNA that accumulates with genomic instability and telomere shortening, the enzyme cyclic GMP-AMP synthase, or cGAS, converts it into the second messenger 2’3′-cyclic GMP-AMP. cGAMP then activates STING, an endoplasmic reticulum-localized transmembrane protein, which traffics through the ER-Golgi intermediate compartment to the Golgi apparatus. There it triggers phosphorylation of TANK-binding kinase 1 and IκB kinase, which in turn activate interferon regulatory factor 3 and nuclear factor-κB, driving a robust induction of type I interferons and interferon-stimulated genes. Beyond antiviral defense, this pathway modulates autophagy, apoptosis, cellular senescence, and metabolism, and it has been implicated in cardiovascular disease, cancer, neurodegeneration, and the aging process itself.

Crucially, STING1/TMEM173 is genetically heterogeneous. A haplotype called HAQ, composed of three missense variants, R71H, G230A, and R293Q, is carried by roughly twenty percent of the human population, with frequencies varying by ethnicity. This haplotype is hypomorphic, meaning it partially impairs function: homozygous HAQ/HAQ individuals show markedly reduced STING protein expression and minimal responsiveness to cyclic dinucleotides, producing far less interferon-beta than wild-type carriers. A second common polymorphism, R232H, impairs sensing of viral and bacterial cyclic dinucleotides, reducing phosphorylation of TBK1 and IRF3, diminishing interferon-alpha transcription, and impairing monocyte function. These variants cumulatively dampen STING-mediated innate immune activation, and prior work has linked them to protection in STING-driven autoinflammatory syndromes such as COPA syndrome, as well as to a decreased risk of aging-associated diseases in population studies.

The rationale for examining these variants in HIV comes from earlier evidence. In a study of Danish long-term non-progressors, the HAQ/HAQ or AQ/AQ genotype was found in about eighteen percent of participants, enriched among these slow progressors but absent in non-controllers receiving therapy. Functional assays showed that carriers displayed reduced innate responses to HIV- and DNA-derived stimuli and lower constitutive type I interferon activation, suggesting that attenuated STING signaling may slow disease progression by limiting the chronic interferon-driven immune activation that erodes T cell homeostasis. Yet beyond that single cohort, virtually nothing was known about how these variants affect systemic inflammation, comorbidity burden, or cognitive and physical outcomes in aging people living with HIV, a rapidly expanding segment of the global HIV population.

To address this gap, the Brescia team conducted a cross-sectional, single-center pilot study of sixty people living with HIV, all over fifty years old, diagnosed at least a decade earlier, and stably maintained on antiretroviral therapy. Participants were recruited between November 2019 and February 2020 at the outpatient HIV clinic of the Spedali Civili Hospital in Brescia, Italy. Genomic DNA was extracted from peripheral blood and the relevant regions of STING1/TMEM173 were amplified by PCR and sequenced directly by the Sanger method, allowing classification of carriers of the R71H, G230A, R293Q, and R232H polymorphisms. The researchers then compared genotype groups across a battery of outcomes: viro-immunological parameters, comorbidities defined by standardized clinical criteria, cognitive performance assessed with the Mini-Mental State Examination and the Clock Drawing Test, and physical function measured with the Short Physical Performance Battery, with appropriate statistical controls for age, education, and duration of HIV infection.

The cohort itself reflected the burden of long-term infection. Forty-five of the sixty participants were male, the median age was 69.5 years, and the median time on antiretroviral therapy was eighteen years. All patients had undetectable plasma HIV RNA, with a median CD4-positive T cell count of 546 cells per cubic millimeter. Comorbidities were common: hypertriglyceridemia affected 38.3 percent, hypercholesterolemia 35 percent, liver disease 33.3 percent, hypertension 31.7 percent, and cardiovascular disease 26.7 percent, and 58.3 percent of patients carried at least two comorbidities. Genotyping revealed that 21 participants, or 35 percent, carried the HAQ haplotype or its partial forms, 14 carried the H232 allele, and 28 were wild-type at all four positions.

The headline finding concerned metabolism. Carriers of the HAQ haplotype, or of any of its three linked polymorphisms, showed a significantly lower prevalence of dyslipidemia compared with wild-type patients, and this difference persisted even when the analysis excluded individuals who also carried the H232 variant and even after adjusting for the duration of HIV infection. Carriers of these hypomorphic alleles also tended to have a lower mean number of comorbidities overall. The authors interpret this as a possible consequence of a lower systemic inflammatory tone, mediated by diminished type I interferon signaling and reduced inflamm-aging. The interpretation gains plausibility from experimental literature showing that STING signaling is tightly linked to lipid homeostasis: STING deficiency in mice protects against adipose tissue inflammation, elevated circulating lipids, insulin resistance, and hepatic steatosis, while STING has been shown to inhibit the fatty acid desaturase FADS2, an enzyme central to polyunsaturated fatty acid metabolism. In pathological settings of chronic STING activation, such as persistent HIV infection, this modulation may contribute to metabolic comorbidities like dyslipidemia, so partially blunted STING function could plausibly be protective.

The immune findings were equally striking, though in the opposite direction. Carriers of the H232 variant showed significantly higher CD4-positive T cell counts than wild-type individuals or all other patients combined, despite similar age and disease duration, suggesting that partial impairment of STING function may support CD4 T cell homeostasis during immune recovery. The most dramatic illustration came from two rare individuals. The cohort’s single HAQ/HAQ homozygote, a 77-year-old man diagnosed 21 years earlier after presenting with disseminated cytomegalovirus infection, esophageal candidiasis, and non-tuberculous mycobacterial infection, now maintains only partial but sufficient viro-immunological control with 477 CD4 cells per cubic millimeter and no severe clinical outcomes. Even more remarkable was the sole H232/H232 homozygote, an 85-year-old woman with a 34-year history of HIV infection who has never started antiretroviral therapy, yet has maintained undetectable viremia, high CD4 counts of 656 cells per cubic millimeter, a normal CD4-to-CD8 ratio of 1.03, normal cognition, and normal motor performance throughout decades of follow-up. She may represent a further example of a STING variant contributing to spontaneous viral control in a long-term non-progressor.

Not every question was resolved. No significant differences emerged between genotype groups in cognitive performance on the MMSE and Clock Drawing Test or in physical performance on the SPPB, possibly because the small sample lacked power to detect subtle effects, or because the screening instruments used are insensitive to the frontal and executive deficits characteristic of HIV-associated neurocognitive impairment. The authors are candid about the limitations: the sample was small and retrospective, homozygotes were vanishingly rare, data on specific antiretroviral drug classes were unavailable as a potential confounder for dyslipidemia, and no direct measurements of interferon or cytokines were made, so the mechanistic link between genotype and clinical outcome remains inferred from prior in vitro and animal work rather than demonstrated in the cohort itself. The findings must therefore be considered strictly exploratory.

Even so, the study opens a genuinely new line of inquiry into why aging people living with HIV diverge so widely in their comorbidity trajectories. If common, partially disabling variants in a single innate immune sensor can shift the balance between chronic inflammation and metabolic or immunological resilience, then the cGAS-STING axis may be a determinant of healthspan in long-treated HIV infection, and perhaps a target for intervention. The authors call for larger, prospective studies integrating inflammatory biomarkers and transcriptomic profiling to confirm whether hypomorphic STING1/TMEM173 variants truly predict immuno-metabolic resilience, and to clarify how this ancient DNA-sensing pathway, so essential for antiviral defense, can become both a driver of aging-related disease and, when quietly weakened, an unexpected ally of longevity.

Subject of Research: Hypomorphic STING1/TMEM173 gene variants and immuno-metabolic outcomes in aging people living with HIV

Article Title: Hypomorphic STING1/TMEM173 variants may support immuno-metabolic resilience in aging people living with HIV

Article References: Zanella, I., Fornari, C., Cesanelli, F., Tiecco, G., Zacchi, E., Bouros, C., Codenotti, S., Ferraro, R. M., Fanzani, A., Giliani, S., & Quiros-Roldan, E. (2026). Hypomorphic STING1/TMEM173 variants may support immuno-metabolic resilience in aging people living with HIV. GeroScience. https://doi.org/10.1007/s11357-026-02561-9

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02561-9

Keywords: STING1, TMEM173, cGAS-STING pathway, HIV, aging, immunosenescence, dyslipidemia, CD4 T cells, polymorphism, inflammaging, long-term non-progressors, antiretroviral therapy